Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo. Patients with resectable (surgically unremovable) non-small cell lung cancer ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer. The Food and Drug Administration (FDA) has approved neoadjuvant (presurgical) ...

Opdivo’s U.S. patent loss is expected in 2028, Europe in 2030, and Japan in 2031. Another cancer drug, Yervoy (ipilimumab), is expected to lose market exclusivity in 2025 in the U.S. and Japan ...

Risk of disease recurrence or death was reduced by 42% with Opdivo compared to chemotherapy. 18-month event-free survival was 70% for Opdivo-treated patients, versus 50% for chemotherapy.

1. U.S. Food and Drug Administration approves perioperative treatment of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable non ...

Last week’s NICE rejection of Opdivo for routine use in lung cancer patients has presented BMS with another setback – and an opportunity for Merck Sharp & Dohme (Merck in the US) and its rival ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

Currently, only approximately 30% of patients who receive Merck & Co., Inc.'s Keytruda® (pembrolizumab) or Bristol Myers Squibb's Opdivo® (nivolumab) will have lasting clinical responses to ...

BMS’ Opdivo is said to be the only PD-1 inhibitor to demonstrate an advantage over chemotherapy, both presurgery and in a perioperative setting. Credit: HJBC via Shutterstock. Bristol Myers Squibb ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market entry ...

Opdivo carries a very high cost in the US – $12,500 a month or $150,000 for patients who stay on the drug for a year, but BMS is likely to offer the drug at a discount on this level in Europe ...